National Bank of Canada FI Sells 261,720 Shares of Humana Inc. (NYSE:HUM)

Key Points

• National Bank of Canada FI reduced its stake in Humana Inc. by 52.9%, selling over 261,720 shares in the first quarter, resulting in ownership of 233,258 shares valued at approximately $61.7 million.
• Humana's stock has seen a variety of analyst ratings; government reports show 17 hold ratings and 7 buy ratings, with a consensus target price of around $281.62.
• In its latest earnings report, Humana reported $6.27 earnings per share, missing expectations, but its revenue was up 9.6% year-over-year to about $32.39 billion.

National Bank of Canada FI lessened its position in Humana Inc. (NYSE:HUM - Free Report) by 52.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 233,258 shares of the insurance provider's stock after selling 261,720 shares during the quarter. National Bank of Canada FI owned approximately 0.19% of Humana worth $61,720,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Cary Street Partners Investment Advisory LLC increased its stake in shares of Humana by 63.9% in the first quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider's stock valued at $31,000 after buying an additional 46 shares in the last quarter. Applied Finance Capital Management LLC lifted its holdings in Humana by 1.7% in the first quarter. Applied Finance Capital Management LLC now owns 2,943 shares of the insurance provider's stock valued at $779,000 after buying an additional 48 shares during the period. Achmea Investment Management B.V. boosted its stake in Humana by 0.5% in the first quarter. Achmea Investment Management B.V. now owns 10,379 shares of the insurance provider's stock valued at $2,746,000 after acquiring an additional 49 shares during the last quarter. Beech Hill Advisors Inc. grew its holdings in Humana by 6.1% during the 1st quarter. Beech Hill Advisors Inc. now owns 865 shares of the insurance provider's stock worth $229,000 after acquiring an additional 50 shares during the period. Finally, Deseret Mutual Benefit Administrators grew its holdings in Humana by 15.8% during the 1st quarter. Deseret Mutual Benefit Administrators now owns 462 shares of the insurance provider's stock worth $122,000 after acquiring an additional 63 shares during the period. Hedge funds and other institutional investors own 92.38% of the company's stock.

Humana Stock Performance

Shares of NYSE HUM traded up $0.51 during midday trading on Monday, hitting $267.19. 1,749,494 shares of the company's stock were exchanged, compared to its average volume of 2,029,327. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.69. Humana Inc. has a 12 month low of $206.87 and a 12 month high of $382.72. The company's 50 day moving average price is $237.88 and its 200 day moving average price is $253.89. The firm has a market capitalization of $32.13 billion, a PE ratio of 20.51, a price-to-earnings-growth ratio of 1.57 and a beta of 0.44.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.32 by ($0.05). The business had revenue of $32.39 billion during the quarter, compared to the consensus estimate of $31.85 billion. Humana had a net margin of 1.28% and a return on equity of 13.67%. During the same period in the prior year, the firm earned $6.96 EPS. The business's revenue for the quarter was up 9.6% on a year-over-year basis. As a group, analysts predict that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HUM has been the subject of several analyst reports. Wells Fargo & Company set a $348.00 target price on Humana in a research report on Friday, July 18th. Oppenheimer increased their price objective on shares of Humana from $300.00 to $310.00 and gave the stock an "outperform" rating in a research report on Thursday, May 1st. Robert W. Baird dropped their price objective on shares of Humana from $300.00 to $297.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. Raymond James Financial raised Humana from a "market perform" rating to an "outperform" rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Finally, Wall Street Zen downgraded shares of Humana from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. Seventeen research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $281.62.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.